Thymosin Alpha-1

FDA Approved

Immune Support

A thymic peptide that modulates immune function, enhances T-cell activity, and supports the body's defense against infections and cancer.

Administration

Subcutaneous injection

Dosage Range

1.6 mg twice weekly

Mechanism of Action

Thymosin Alpha-1 activates dendritic cells, enhances T-cell differentiation and maturation, increases NK cell activity, and modulates cytokine production to optimize immune surveillance.

Clinical Benefits

Enhances immune surveillance

Supports cancer immunotherapy

Improves vaccine response

Fights chronic viral infections

Reduces immunosuppression

Clinical Evidence

FDA orphan drug status for hepatitis B. Approved in 35+ countries for hepatitis B/C treatment. Clinical trials show improved outcomes in cancer immunotherapy combinations.

Side Effects

Injection site reaction

Mild fatigue

Muscle aches (rare)

Contraindications

Organ transplant recipients

Autoimmune conditions (monitor)

Pregnancy

Related Peptides in Immune Support

LL-37

A human antimicrobial peptide (cathelicidin) with broad-spectrum antimicrobial, anti-biofilm, and immunomodulatory properties.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.